[-] Show simple item record

dc.contributor.authorFagan, Heather Bittnereng
dc.contributor.authorMoeller, Amy Hollihaneng
dc.date.issued2004eng
dc.description.abstractFour antiviral agents have been approved by the U.S. Food and Drug Administration for the treatment of influenza infection: amantadine (Symmetrel), oseltamivir (Tamiflu), rimantadine (Flumadine), and zanamivir (Relenza). No head-to-head trials have compared the effectiveness of these agents, and no direct evidence exists regarding their relative efficacy. In the absence of specific contraindications, amantadine and rimantadine are preferred for use in most patients because these two agents cost less than the other two. Patients with renal insufficiency or a seizure disorder should not take amantadine, and patients with chronic obstructive pulmonary disease or asthma should not take zanamivir. [Strength of recommendation: C]eng
dc.identifier.urihttp://hdl.handle.net/10355/3929eng
dc.languageEnglisheng
dc.publisherFamily Physicians Inquiries Networkeng
dc.relation.ispartofcollectionClinical Inquiries, 2004 (MU)eng
dc.relation.ispartofcommunityUniversity of Missouri--Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Networkeng
dc.relation.ispartofseriesAmerican family physician, 70, no. 07 (October 2004)eng
dc.rightsOpenAccess.eng
dc.rights.licenseThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.eng
dc.subjectduration of symptomseng
dc.subject.lcshOtitis Mediaeng
dc.subject.lcshAntiviral agentseng
dc.subject.lcshInfluenzaeng
dc.titleWhat Is the Best Antiviral Agent for Influenza Infection?eng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record